KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Current Deferred Revenue (2016 - 2017)

Pacira BioSciences (PCRX) has 8 years of Current Deferred Revenue data on record, last reported at $102000.0 in Q4 2017.

  • For Q4 2017, Current Deferred Revenue fell 82.86% year-over-year to $102000.0; the TTM value through Dec 2017 reached $102000.0, down 82.86%, while the annual FY2017 figure was $102000.0, 82.86% down from the prior year.
  • Current Deferred Revenue reached $102000.0 in Q4 2017 per PCRX's latest filing, down from $520000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $1.4 million in Q2 2014 and bottomed at $102000.0 in Q4 2017.
  • Average Current Deferred Revenue over 5 years is $1.1 million, with a median of $1.0 million recorded in 2013.
  • Peak YoY movement for Current Deferred Revenue: plummeted 86.56% in 2013, then soared 46.71% in 2014.
  • A 5-year view of Current Deferred Revenue shows it stood at $1.0 million in 2013, then soared by 41.47% to $1.4 million in 2014, then changed by 0.0% to $1.4 million in 2015, then tumbled by 58.27% to $595000.0 in 2016, then plummeted by 82.86% to $102000.0 in 2017.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $102000.0 in Q4 2017, $520000.0 in Q1 2017, and $595000.0 in Q4 2016.